natgillin/translations-raw huggingface dataset:
Talk to your doctor before taking Kinzalmono if you are suffering or have ever suffered from any of the following conditions or illnesses: 
Obratite se svom liječniku prije nego uzmete Kinzalmono ako imate ili ste ikada imali neko od sljedećih stanja ili bolesti:
What Kinzalmono is and what it is used for What you need to know before you take Kinzalmono How to take Kinzalmono 
Što je Kinzalmono i za što se koristi Što morate znati prije nego počnete uzimati Kinzalmono
Do not take Kinzalmono 
Nemojte uzimati Kinzalmono
If you forget to take Kinzalmono 
Ako ste zaboravili uzeti Kinzalmono
Talk to your doctor before taking Kinzalmono: 
Obratite se svom liječniku prije nego uzmete Kinzalmono:
Some people feel dizzy or tired when taking Kinzalmono. 
Neki ljudi osjećaju omaglicu ili umor kada uzimaju Kinzalmono.
Volume and/or sodium depletion should be corrected prior to administration of Kinzalmono. 
Deplecija volumena i/ili natrija se mora korigirati prije primjene Kinzalmonoa.
There are no adequate data from the use of Kinzalmono in pregnant women. 
Ne postoje odgovarajući podaci o primjeni Kinzalmonoa u trudnica.
The overall incidence of adverse reactions reported with telmisartan (was usually comparable to placebo (41.4 % vs 43.9 %) in controlled trials in patients treated for hypertension. 
Ukupna incidencija nuspojava zabilježenih s telmisartanom bila je uobičajeno usporediva s placebom (41,4 % u odnosu na 43,9 %) u kontroliranim ispitivanjima u bolesnika liječenih zbog hipertenzije.
You should consult with your doctor if you need to adjust the dose of your other medicine while taking Kinzalmono. 
Potrebno je posavjetovati se s liječnikom ako trebate prilagodbu doze drugih lijekova koje uzimate istodobno s Kinzalmonom.
Kinzalmono is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely. 
Kinzalmono se ne preporučuje dojiljama te Vaš liječnik može odabrati drugo liječenje za Vas ako želite dojiti, osobito ako je Vaše dijete novorođenče ili je prerano rođeno.
At the beginning of the preventive therapy with Kinzalmono 80 mg, blood pressure should be frequently monitored. 
Na početku preventivnog liječenja s Kinzalmonom od 80 mg, krvni tlak treba redovito pratiti.
There is no experience regarding the administration of Kinzalmono in patients with recent kidney transplantation. 
Ne postoji iskustvo u vezi primjene Kinzalmonoa u bolesnika kojima je nedavno transplantiran bubreg.
What you need to know before you take Kinzalmono 
Što morate znati prije nego počnete uzimati Kinzalmono
Such conditions should be corrected before the administration of Kinzalmono. 
Takva stanja moraju se korigirati prije primjene Kinzalmonoa.
Kinzalmono is used to treat essential hypertension (high blood pressure) in adults. 
Kinzalmono se primjenjuje u liječenju esencijalne hipertenzije (visoki krvni tlak) u odraslih osoba.
Kinzalmono may be less effective in lowering the blood pressure in black patients. 
Kinzalmono može biti manje učinkovit u snižavanju krvnog tlaka u bolesnika crne rase.
As with other medicinal products acting on the renin-angiotensin-aldosterone-system, telmisartan may provoke hyperkalaemia (see section 4.4). 
Poput ostalih lijekova koji djeluju na sustav renin-angiotenzin-aldosteron, telmisartan može izazvati hiperkalijemiju (vidjeti dio 4.4).
Kinzalmono belongs to a class of medicines known as angiotensin II receptor antagonists. 
Kinzalmono pripada skupini lijekova poznatih kao antagonisti receptora angiotenzina II.
When driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy such as Kinzalmono. 
Prilikom upravljanja vozilima ili strojevima, povremeno može doći do pojave omaglice ili pospanosti, kada se uzima antihipertenzivna terapija poput Kinzalmonoa.
What Kinzalmono contains 
Što Kinzalmono sadrži
Because no information is available regarding the use of Kinzalmono during breast-feeding, Kinzalmono is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant. 
Budući da ne postoje dostupni podaci o primjeni Kinzalmonoa tijekom dojenja, primjena Kinzalmonoa se ne preporučuje i prednost se daje drugim lijekovima s bolje utvrđenim sigurnosnim profilima tijekom dojenja, osobito tijekom razdoblja dojenja novorođenčeta ili nedonoščeta.
Telmisartan tablets are for once-daily oral administration and should be taken with liquid with or without food. 
Telmisartan tablete primjenjuju se peroralno jedanput na dan i trebaju se uzimati s tekućinom, sa ili bez hrane.
The effect of Kinzalmono may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen) or corticosteroids. 
Učinak Kinzalmonoa se može smanjiti kada uzimate NSAIL (nesteroidne protupalne lijekove, npr. aspirin ili ibuprofen) ili kortikosteroide.
Kinzalmono may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine). 
Kinzalmono može povećati učinak snižavanja krvnog tlaka drugih lijekova koji se primjenjuju u liječenju visokog krvnog tlaka ili lijekova s potencijalnim učincima na snižavanje krvnog tlaka (npr. baklofen, amifostin).
If you are intolerant to some sugars, consult your doctor before taking Kinzalmono. 
Ako ne podnosite neke šećere, posavjetujte se sa svojim liječnikom prije uzimanja Kinzalmonoa.
For reduction of cardiovascular events, the usual dose of Kinzalmono is one 80 mg tablet once a day. 
Za smanjivanje kardiovaskularnih događaja, uobičajena doza Kinzalmonoa je jedna tableta od 80 mg, jedanput na dan.
Kinzalmono is also used to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk because they have a reduced or blocked blood supply to the heart or legs, or have had a stroke or have high risk diabetes. 
Kinzalmono se također primjenjuje za smanjivanje kardiovaskularnih događaja (tj. srčanog udara ili moždanog udara) u rizičnih odraslih osoba koji imaju smanjenu ili prekinutu opskrbu krvlju srca ili nogu, ili su imali moždani udar, ili imaju šećernu bolest s visokim rizikom za oštećenje organa.
The concomitant use of Kinzalmono with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5, and 5.1). 
Istodobna primjena Kinzalmona s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
Symptomatic hypotension, especially after the first dose of Kinzalmono, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting. 
Simptomatska hipotenzija, osobito nakon prve doze Kinzalmonoa, može se pojaviti u bolesnika koji imaju depleciju volumena i/ili natrija zbog snažne terapije diureticima, prehrane s ograničenim unosom soli, proljeva ili povraćanja.
Remove your Kinzalmono tablet from the blister only directly prior to intake. 
Izvadite Kinzalmono tabletu iz blistera neposredno prije unosa.
This applies especially to the medicines listed below taken at the same time with Kinzalmono: 
Ovo se osobito odnosi na lijekove koji su navedeni u nastavku, a uzimaju se istovremeno s Kinzalmonom:
Children and adolescents The use of Kinzalmono in children and adolescents up to the age of 18 years is not recommended. 
Djeca i adolescenti Primjena Kinzalmonoa u djece i adolescenata do dobi od 18 godina se ne preporučuje.
Kinzalmono is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile. 
Kinzalmono se ne smije davati bolesnicima s kolestazom, bilijarnom opstrukcijom ili teškim oštećenjem jetrene funkcije (vidjeti dio 4.3), s obzirom da se telmisartan uglavnom eliminira putem žuči.
The safety and efficacy of Kinzalmono in children and adolescents aged below 18 years have not been established. 
Sigurnost i djelotvornost Kinzalmonoa u djece i adolescenata u dobi ispod 18 godina nisu ustanovljene.
In preclinical studies, no effects of Kinzalmono on male and female fertility were observed. 
U nekliničkim ispitivanjima učinci Kinzalmonoa na plodnost muškaraca i žena nisu uočeni.
Kinzalmono contains sorbitol. 
Kinzalmono sadrži sorbitol.
How to take Kinzalmono 
Kako uzimati Kinzalmono
When Kinzalmono is used in patients with impaired renal function, periodic monitoring of potassium and creatinine serum levels is recommended. 
Kada se Kinzalmono primjenjuje u bolesnika s poremećenom funkcijom bubrega, preporučuje se povremeno pratiti vrijednosti kalija i kreatinina u serumu.
• Diuretics ('water tablets'), especially if taken in high doses together with Kinzalmono, may lead to excessive loss of body water and low blood pressure (hypotension). 
• Diuretici ('tablete za mokrenje'), osobito ako se uzimaju visoke doze zajedno s Kinzalmonom, mogu dovesti do prekomjernog gubitka vode u tijelu te niskog krvnog tlaka (hipotenzija).
Kinzalmono is contraindicated in patients with severe hepatic impairment (see section 4.3). 
Kinzalmono je kontraindiciran u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.3).
If any of the above applies to you, tell your doctor or pharmacist before taking Kinzalmono. 
Ako se nešto od prethodno navedenog odnosi na Vas, obavijestite liječnika ili ljekarnika prije početka uzimanja Kinzalmonoa.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Unit dose blister (28 x 1 tablets pack) 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Blister djeljiv na jedinične doze (pakiranje s 28 x 1 tabletom)
Kinzalmono blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered. 
Kinzalmono blokira učinak angiotenzina II, tako da se krvne žile šire, a krvni tlak snižava.
QUALITATIVE AND QUANTITATIVE COMPOSITION Kinzalmono 20 mg tablets 
KVALITATIVNI I KVANTITATIVNI SASTAV Kinzalmono 20 mg tablete
If you take more Kinzalmono than you should If you accidentally take too many tablets, contact your doctor, pharmacist, or your nearest hospital emergency department immediately. 
Ako ste slučajno uzeli previše tableta, odmah se obratite svom liječniku, ljekarniku ili u hitnu službu najbliže bolnice.
How to store Kinzalmono 
Kako čuvati Kinzalmono
Eye disorders: Rare: 
Poremećaji oka Rijetko:
Possible side effects of Kinzalmono 
Moguće nuspojave Kinzalmonoa
Kinzalmono 20 mg tablets Pack sizes: Blister with 14, 28, 56 or 98 tablets. 
Kinzalmono 20 mg tablete Veličine pakiranja: Blister s 14, 28, 56, ili 98 tableta.
Kinzalmono may also be used in combination with diuretics ('water tablets') such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with Kinzalmono. 
Kinzalmono se također može primjenjivati u kombinaciji s diureticima (tablete za mokrenje), kao što je hidroklorotiazid za koji se pokazalo da ima dodatan učinak snižavanja krvnog tlaka s Kinzalmonom.
Kinzalmono is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section). 
Kinzalmono se ne preporučuje u ranoj trudnoći i ne smije se uzimati ako ste trudni dulje od 3 mjeseca jer može izazvati teška oštećenja Vašeg djeteta ako se primjenjuje u ovom stadiju (vidjeti dio o trudnoći).
For treatment of high blood pressure, the usual dose of Kinzalmono for most patients is one 40 mg tablet once a day to control blood pressure over the 24 hour period. 
Za terapiju povišenog krvnog tlaka uobičajena doza Kinzalmonoa za većinu bolesnika je jedna tableta od 40 mg jedanput na dan za kontrolu krvnog tlaka tijekom 24 sata.
Kinzalmono should be used only with caution in patients with mild to moderate hepatic impairment. 
Kinzalmono se treba primjenjivati isključivo s oprezom u bolesnika s blagim do umjerenim oštećenjem jetrene funkcije.
Kinzalmono 40 mg and 80 mg tablets 4 years 
Kinzalmono 40 mg i 80 mg tablete 4 godine
Kinzalmono 20 mg tablets 3 years 
Kinzalmono 20 mg tablete 3 godine
(It is also better to avoid Kinzalmono in early pregnancy - see pregnancy section.) 
• Ako ste dulje od 3 mjeseca trudni (također je bolje izbjegavati Kinzalmono u ranoj trudnoći vidjeti dio o trudnoći).
Kinzalmono is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. 
Kinzalmono se ne preporučuje u ranoj trudnoći te se ne smije uzimati ako ste trudni dulje od 3 mjeseca jer može izazvati teška oštećenja djeteta ako se primjenjuje nakon trećeg mjeseca trudnoće.
Kinzalmono is available in blister packs containing 14, 28, 56 or 98 tablets. 
Kinzalmono je dostupan u blister pakiranjima od 14, 28, 56 ili 98 tableta.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 16 December 1998 
DATUM PRVOG ODOBRENJA / DATUM OBNOVE ODOBRENJA
Kinzalmono 40 mg tablets White oblong tablets of 3.8 mm engraved with the code number '51H' on one side. 
Kinzalmono 40 mg tablete Bijele, duguljaste tablete od 3,8 mm s utisnutom oznakom „51H“ na jednoj strani.
Kinzalmono 80 mg tablets White oblong tablets of 4.6 mm engraved with the code number '52H' on one side. 
Kinzalmono 80 mg tablete Bijele, duguljaste tablete od 4,6 mm s utisnutom oznakom „52H“ na jednoj strani.
Kinzalmono 40 mg tablets 
Kinzalmono 40 mg tablete
INFORMATION IN BRAILLE Kinzalmono 20 mg 
16. PODACI NA BRAILLEOVOM PISMU Kinzalmono 20 mg
INFORMATION IN BRAILLE Kinzalmono 80 mg 
16. PODACI NA BRAILLEOVOM PISMU Kinzalmono 80 mg
INFORMATION IN BRAILLE Kinzalmono 40 mg 
16. PODACI NA BRAILLEOVOM PISMU Kinzalmono 40 mg
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non-steroidal antiinflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim). 
Rizik od hiperkalijemije se povećava u slučaju kombinacije s drugim lijekovima koji također mogu izazvati hiperkalijemiju (nadomjesci soli koji sadrže kalij, diuretici koji štede kalij, ACE-inhibitori, antagonisti receptora angiotenzina II, nesteroidni protuupalni lijekovi (NSAIL, uključujući selektivne COX-2 inhibitore), heparin, imunosupresivi (ciklosporin ili takrolimus) i trimetoprim).
What Kinzalmono looks like and contents of the pack Kinzalmono 40 mg tablets are white, oblong-shaped and engraved with the code number '51H' on one side. 
Kako Kinzalmono izgleda i sadržaj pakiranja Kinzalmono 40 mg tablete su bijele, duguljastog oblika, s utisnutom oznakom „51H“ na jednoj strani.
Kinzalmono 80 mg tablets 
Kinzalmono 80 mg tablete
Kinzalmono 20 mg tablets 
Kinzalmono 20 mg tablete
What Kinzalmono looks like and contents of the pack Kinzalmono 80 mg tablets are white, oblong-shaped and engraved with the code number '52H' on one side. 
Kako Kinzalmono izgleda i sadržaj pakiranja Kinzalmono 80 mg tablete su bijele, duguljastog oblika, s utisnutom oznakom „52H“ na jednoj strani.
Kinzalmono is available in blister packs containing 14, 28, 56 or 98 tablets, or unit dose blister packs containing 28 x 1 tablets. 
Kinzalmono je dostupan u blister pakiranjima od 14, 28, 56 ili 98 tableta, ili blisterima djeljivim na jedinične doze s 28 x 1 tabletom.
Kinzalmono 20 mg tablets EU/1/98/091/009 (14 tablets) EU/1/98/091/010 (28 tablets) EU/1/98/091/011 (56 tablets) EU/1/98/091/012 (98 tablets) 
Kinzalmono 20 mg tablete EU/1/98/091/009 (14 tableta) EU/1/98/091/010 (28 tableta) EU/1/98/091/011 (56 tableta) EU/1/98/091/012 (98 tableta)
Kinzalmono 40 mg tablets EU/1/98/091/001 (14 tablets) EU/1/98/091/002 (28 tablets) EU/1/98/091/003 (56 tablets) EU/1/98/091/004 (98 tablets) EU/1/98/091/013 (28 x 1 tablets) 
Kinzalmono 40 mg tablete EU/1/98/091/001 (14 tableta) EU/1/98/091/002 (28 tableta) EU/1/98/091/003 (56 tableta) EU/1/98/091/004 (98 tableta) EU/1/98/091/013 (28 x 1 tableta)
In the "Prevention Regimen For Effectively avoiding Second Strokes" (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.002.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)]. 
godina i starijih, koji su nedavno imali moždani udar, zabilježena je povećana incidencija sepse za telmisartan u usporedbi s placebom, 0,70 % u odnosu na 0,49 % RR 1,43 (95 % interval pouzdanosti 1,00 - 2,06).
Haemoglobin decreased, blood uric acid increased, hepatic enzyme increased, blood creatine phosphokinase increased 
Sniženi hemoglobin, povišene vrijednosti mokraćne kiseline u krvi, povišeni jetreni enzimi, povišena kreatin-fosfokinaza u krvi za daljnje opise, molimo vidjeti pod “Opis odabranih nuspojava”.
Kinzalmono 80 mg tablets EU/1/98/091/005 (14 tablets) EU/1/98/091/006 (28 tablets) EU/1/98/091/007 (56 tablets) EU/1/98/091/008 (98 tablets) EU/1/98/091/014 (28 x 1 tablets) 
Kinzalmono 80 mg tablete EU/1/98/091/005 (14 tableta) EU/1/98/091/006 (28 tableta) EU/1/98/091/007 (56 tableta) EU/1/98/091/008 (98 tableta) EU/1/98/091/014 (28 x 1 tableta)
Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), severe allergic reaction (anaphylactic reaction), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), upset stomach, dry mouth, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood. 
Sepsa* (često nazvana „trovanje krvi“ je teška infekcija s upalnim odgovorom cijelog organizma što može dovesti do smrtnog ishoda), povećanje određenih bijelih krvnih stanica (eozinofilija), nizak broj krvnih pločica (trombocitopenija), teška alergijska reakcija (anafilaktička reakcija), alergijska reakcija (npr. osip, svrbež, otežano disanje, piskanje, oticanje lica ili nizak krvni tlak), niske razine šećera u krvi (u bolesnika sa šećernom bolesti), osjećaj tjeskobe, izrazita pospanost, oštećen vid, ubrzani otkucaji srca (tahikardija), suhoća usta, nadražaj želuca, poremećaj osjeta okusa (disgeuzija), abnormalna funkcija jetre (vjerojatnost da će iskusiti ovu nuspojavu, veća je za bolesnike iz Japana), brzo oticanje kože i sluznice koji mogu dovesti do smrtnog ishoda (angioedem također sa smrtnim ishodom), ekcem (poremećaj kože), crvenilo kože, koprivnjača (urtikarija), težak osip od lijeka, bol u zglobovima (artralgija), bol u udovima, bol tetiva, simptomi nalik gripi, snižen hemoglobin (krvni protein), povišena razina mokraćne kiseline, povišeni jetreni enzimi ili kreatin fosfokinaza u krvi.
Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, upset stomach, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood. 
Sepsa* (često nazvana „trovanje krvi“ je teška infekcija s upalnim odgovorom cijelog organizma što može dovesti do smrtnog ishoda), povećanje određenih bijelih krvnih stanica (eozinofilija), nizak broj krvnih pločica (trombocitopenija), teška alergijska reakcija (anafilaktička reakcija), alergijska reakcija (npr. osip, svrbež, otežano disanje, piskanje, oticanje lica ili nizak krvni tlak), niske razine šećera u krvi (u bolesnika sa šećernom bolesti), osjećaj tjeskobe, izrazita pospanost, oštećen vid, ubrzani otkucaji srca (tahikardija), suhoća usta, nadražaj želuca, poremećaj osjeta okusa (digeuzija), abnormalna funkcija jetre (vjerojatnost da će iskusiti ovu nuspojavu, veća je za bolesnike iz Japana), brzo oticanje kože i sluznice koji mogu dovesti do smrtnog ishoda (angioedem također sa smrtnim ishodom), ekcem (poremećaj kože), crvenilo kože, koprivnjača (urtikarija), težak osip od lijeka, bol u zglobovima (artralgija), bol u udovima, bol tetiva, simptomi nalik gripi, snižen hemoglobin (krvni protein), povišena razina mokraćne kiseline, povišeni jetreni enzimi ili kreatin fosfokinaza u krvi.
Package leaflet: Information for the user Kinzalmono 20 mg tablets Telmisartan 
Uputa o lijeku: Informacije za korisnika Kinzalmono 20 mg tablete telmisartan
Package leaflet: Information for the user Kinzalmono 40 mg tablets Telmisartan 
Uputa o lijeku: Informacije za korisnika Kinzalmono 40 mg tablete telmisartan
Package leaflet: Information for the user Kinzalmono 80 mg tablets Telmisartan 
Uputa o lijeku: Informacije za korisnika Kinzalmono 80 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Kinzalmono 40 mg tablets telmisartan 
NAZIV LIJEKA Kinzalmono 40 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Kinzalmono 80 mg tablets telmisartan 
NAZIV LIJEKA Kinzalmono 80 mg tablete telmisartan
NAME OF THE MEDICINAL PRODUCT Kinzalmono 20 mg tablets telmisartan 
NAZIV LIJEKA Kinzalmono 20 mg tablete telmisartan
Kinzalmono 40 mg and 80 mg tablets Pack sizes: Blister with 14, 28, 56 or 98 tablets or perforated unit dose blisters with 28 x 1 tablets. 
Veličine pakiranja: blister s 14, 28, 56 ili 98 tableta ili perforirani blisteri djeljivi na jedinične doze s 28 x 1 tabletom.
What Kinzalmono looks like and contents of the pack Kinzalmono 20 mg tablets are white, round and engraved with the code number '50H' on one side and the company logo on the other side. 
Kinzalmono 20 mg tablete su bijele, okrugle s utisnutom oznakom „50H“ na jednoj i logom tvrtke na drugoj strani.
This treatment course is repeated one year later. 
Ovakav raspored liječenja ponavlja se nakon godinu dana.
It must not be given to patients with active cancers. 
Ne smije se primjenjivati u bolesnika s aktivnim rakom.
The full EPAR for Mavenclad can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Mavenclad nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.